BioMarin reported Q1 2026 total revenues of $766 million, with net product revenues of $760 million56
Alexander Hardy, President and CEO, hosted the first quarter 2026 financial results conference call and webcast on Monday, May 4, 2026, at 4:
30 p.m. ET13
Enzyme therapies segment revenues grew 6% year-over-year in Q1 20265
Voxzogo patient count grew more than 20% in Q1 20265
BioMarin's 2025 full-year revenue was $3.22 billion, up 13% year-over-year, with Q4 2025 revenue of $875 million3
The company provided 2026 revenue guidance of $3.325-3.425 billion and non-GAAP diluted EPS guidance of $4.95-5.153
Sources:
1. https://investors.biomarin.com/news/news-details/2026/BioMarin-to-Host-First-Quarter-2026-Financial-Results-Conference-Call-and-Webcast-on-Monday-May-4-2026-at-430pm-ET/default.aspx
3. https://www.stocktitan.net/news/BMRN/bio-marin-to-host-first-quarter-2026-financial-results-conference-loiezujv8hco.html
5. https://www.marketbeat.com/earnings/reports/2026-5-4-biomarin-pharmaceutical-inc-stock/
6. https://investors.biomarin.com/financials/quarterly-results/default.aspx